Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ACP1 | P24666 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RHOC | P08134 | 1/20 | 0.42 |
| ▸ | RHOA | P61586 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1444611 | 0.89 | LMNA (0.50) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL1444131 | 0.85 | LMNA (0.52) | LMNAACP1ALDH1A1TACR1MAPT | |
| Hydrochloric Acid SCHEMBL1445368 | 0.84 | LMNA (0.51) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL13568424 | 0.82 | EPHX2 (0.59) | LMNAACP1ALDH1A1TACR1MEN1 | |
| SCHEMBL6871047 | 0.80 | ACP1 (0.49) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL3895469 | 0.79 | LMNA (0.52) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL3889819 | 0.79 | LMNA (0.52) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL3889815 | 0.79 | LMNA (0.52) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL26087834 | 0.78 | LMNA (0.55) | LMNAMAPTMEN1KMT2A | |
| SCHEMBL20094430 | 0.78 | RHOC (0.50) | LMNAACP1TACR1MAPTGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| WO-2011032291-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD . (CA) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011032291-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD . (CA) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1I, CACNA1H | LMNA 847/4885ACP1 2139/4885ALDH1A1 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.